{"id":43981,"date":"2022-05-17T11:01:32","date_gmt":"2022-05-17T09:01:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/"},"modified":"2022-05-17T11:01:32","modified_gmt":"2022-05-17T09:01:32","slug":"osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/","title":{"rendered":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–Osivax<\/a>, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining Osivax\u2019 T-cell based influenza candidate, OVX836, with a range of the NIAID Vaccine Research Center (VRC)\u2019s influenza vaccine candidates. The immune responses produced by OVX836 involve T-cells against the nucleoprotein (NP), a highly conserved internal antigen across flu strains, and those produced by the NIAID VRC vaccine candidates involve B-cells against hemagglutinin (HA) surface antigens. As both approaches are directed to potential pandemic influenza strains, Osivax and NIAID will evaluate potential synergies between these respective immune responses and potential additive effects in animal challenge models in an effort to create improved, broad-spectrum influenza vaccines.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThis research collaboration is an extension of our ongoing interactions with NIAID and represents a critical step forward in addressing the urgent need for an improved influenza vaccine to protect against influenza strains with pandemic potential,\u201d commented Alexandre Le Vert, CEO and Co-Founder of Osivax<\/b>. \u201cIn combining OVX836 with the NIAID candidates, we intend to unlock the synergy of pairing T- and B-cell activation to drastically improve influenza protection against future pandemic outbreaks. The data we will gather from this collaboration will be invaluable to this effort.\u201d\n<\/p>\n

\nOsivax\u2019 OVX836 is a nucleoprotein-targeting influenza vaccine developed using the company\u2019s proprietary oligoDOM\u00ae<\/sup> technology. Recently published clinical data<\/a> from the company\u2019s Phase 2a trial revealed that OVX836 induced a significant increase of NP-specific cellular immune responses, including CD4+ and CD8+ T-cells, and initial efficacy signals while being safe and well-tolerated. Osivax is pursuing the combination with the NIAID\u2019s next-generation vaccine candidates as a strategy to significantly improve the efficacy and cross-protection against existing and future pandemic influenza strains.\n<\/p>\n

\nUnder the terms of the collaboration, NIAID will provide its novel, self-assembling ferritin nanoparticles that serve as scaffolding to display multiple copies of HA protein, a protein expressed on the surface of influenza viruses, to Osivax for in vivo<\/i> preclinical studies in combination with OVX836. Preclinical data from the NIAID vaccine candidates indicate an enhanced breadth of the immune response in animal models compared to traditional seasonal vaccines, thus also offering potential protection against influenza strains not included in the vaccine. NIAID is currently conducting Phase 1 clinical trials to assess safety and immunogenicity in humans (NCT03814720<\/a> and NCT04579250<\/a>).\n<\/p>\n

\nAbout OVX836<\/b>\n<\/p>\n

\nOsivax\u2019 influenza vaccine, OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response. Osivax\u2019 oligoDOM\u00ae<\/sup> technology enables the design and production of recombinant version of the NP which self-assembles into a nanoparticle, thus triggering powerful T-and B-cell immune responses. OVX836 has shown promising safety, immunogenicity, and efficacy in preclinical and clinical trials (Phase 1 and Phase 2a).\n<\/p>\n

\nAbout Osivax<\/b>\n<\/p>\n

\nOsivax is a biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM\u00ae<\/sup>, to transform current and new vaccines by generating superior T-cell responses in addition to strong and sustained B cell responses against highly mutating viruses. The company is establishing proof of concept with its highly validated lead influenza candidate, OVX836, which is currently in Phase 2 testing with over 500 subjects tested. Osivax is also exploring the broader application of its technology in both mRNA and subunit vaccines against a variety of indications. The company will expand into other infectious disease indications through combinations and collaborations worldwide.\n<\/p>\n

\nAbout NIAID<\/b>\n<\/p>\n

\nNIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. News releases, fact sheets and other NIAID-related materials are available on the NIAID website<\/a>.\n<\/p>\n

\nFor further information: www.osivax.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAlexandre LE VERT, CEO
\n
contact@osivax.com<\/a>
+33 (0)9-70-30-13-80<\/p>\n

For Media Inquiries
\n
Trophic Communications
\n
Valeria Fisher or Desmond James
\n
Osivax@trophic.eu<\/a>
+49-(0)-172-804-1816
\n
+49-(0)-151-678-59086\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining Osivax\u2019 T-cell based … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-43981","6":"format-standard","7":"category-industry"},"yoast_head":"\nOsivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining Osivax\u2019 T-cell based ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-17T09:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines\",\"datePublished\":\"2022-05-17T09:01:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/\"},\"wordCount\":716,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005130\\\/en\\\/731908\\\/21\\\/Osivax_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/\",\"name\":\"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005130\\\/en\\\/731908\\\/21\\\/Osivax_Logo.jpg\",\"datePublished\":\"2022-05-17T09:01:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005130\\\/en\\\/731908\\\/21\\\/Osivax_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220517005130\\\/en\\\/731908\\\/21\\\/Osivax_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/","og_locale":"en_US","og_type":"article","og_title":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has entered a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a preclinical evaluation combining Osivax\u2019 T-cell based ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-17T09:01:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines","datePublished":"2022-05-17T09:01:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/"},"wordCount":716,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/","url":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/","name":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg","datePublished":"2022-05-17T09:01:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220517005130\/en\/731908\/21\/Osivax_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/osivax-enters-research-collaboration-with-the-niaid-for-the-evaluation-of-combination-approach-to-broad-spectrum-influenza-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=43981"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/43981\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=43981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=43981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=43981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}